Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05826223 · ClinicalTrials.gov registry record
Novel Sepsis Sub-phenotypes Based on Trajectories of Vital Signs
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 1,916
- Enrollment target
NCT05826223: Completed study, sponsored by Emory University.
NCT05826223 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 1,916 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05826223 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 1,916 participants
- Enrollment target
Study Summary
Sepsis is a dysregulated host response to infection resulting in organ dysfunction. Over the past three decades, more than 30 pharmacological therapies have been tested in \>100 clinical trials and have failed to show consistent benefit in the overall population of patients with sepsis. The one-size-fits-all approach has not worked. This has resulted in a shift in research towards identifying sepsis subphenotypes through unsupervised learning. The ultimate objective is to identify sepsis subphenotypes with different responses to therapies, which could provide a path towards the precision medicine approach to sepsis. The investigators have previously discovered sepsis subphenotypes in retrospective data using trajectories of vital signs in the first 8 hours of hospitalization. The team aims to prospectively classify adult hospitalized patients into these subphenotypes in a prospective, observational study. This will be done through the implementation of an electronic health record integrated application that will use vital signs from hospitalized patients to classify the patients into one of four subphenotypes. This study will continue until 1,200 patients with infection are classified into the sepsis subphenotypes. The classification of the patients is only performed to validate the association of the subphenotypes with clinical outcomes as was shown in retrospective studies. Physicians and providers treating the patients will not see the classification, and the algorithm classifying the patients will in no way affect the care of the patients. Further, all the data needed for the algorithm (vital signs from the first 8 hours) are standard of care, and enrollment in the prospective study does not require any additional data.
Primary Outcome
Comparison of 30 day in-hospital mortality rate between the 4 subphenotypes.
Interventions
- OTHER Implementation and evaluation of a sepsis sub-phenotyping algorithm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,916 participants |
| Start Date | 2025-09-18 |
| Est. Completion | 2026-01-14 |
What the finished NCT05826223 record still lists
NCT05826223 is an observational study that tracks outcomes without assigning an intervention. Its 1,916 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Implementation and evaluation of a sepsis sub-phenotyping algorithm is the first listed.
NCT05826223 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05826223 about?
NCT05826223 is a clinical study titled "Novel Sepsis Sub-phenotypes Based on Trajectories of Vital Signs". Sepsis is a dysregulated host response to infection resulting in organ dysfunction. Over the past three decades, more than 30 pharmacological therapies have been tested in \>100 clinical trials and have failed to show consistent benefit in the overall population of patients with sepsis. The one-size...
What is the current status of trial NCT05826223?
This trial is currently completed. The enrollment target is 1,916 participants. The study started on 2025-09-18. Estimated completion is 2026-01-14.
What interventions are being tested in trial NCT05826223?
The interventions under investigation include: Implementation and evaluation of a sepsis sub-phenotyping algorithm (OTHER).
Who is sponsoring clinical trial NCT05826223?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06799117 · 1,912 participants · NA
Adaptive Decision Support for Addiction Treatment Master
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI